NCCN recommends Sirtex's microspheres

Cancer treatment firm Sirtex Medical announced that its resin microspheres have been included as a recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

The company's SIR-Spheres yttrium-90 (Y-90) resin microspheres have been included in NCCN's category 2A clinical practice guidelines in oncology for colon cancer and rectal cancer, according to the firm. The designation signifies that there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with Y-90 microspheres is a viable option in patients with liver-dominant, chemotherapy-resistant colorectal disease.

The new NCCN guidelines are available online.

Page 1 of 461
Next Page